Agrarian School of Viseu (ESAV), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal.
Centre for the Study of Education, Technologies and Health (CI&DETS), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal.
J Diabetes Res. 2017;2017:5164292. doi: 10.1155/2017/5164292. Epub 2017 Aug 27.
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have been carried out revealing its ability to not only improve metabolic control but also ameliorate dysfunction in various diabetes-targeted organs, especially the kidney, due to putative underlying cytoprotective properties, namely, its antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties. Despite overall recommendations, many patients spend a long time well outside the recommended glycaemic range and, therefore, have an increased risk for developing micro- and macrovascular complications. Currently, it is becoming clearer that type 2 diabetes mellitus (T2DM) management must envision not only the improvement in glycaemic control but also, and particularly, the prevention of pancreatic deterioration and the evolution of complications, such as DN. This review aims to provide an overview of the current knowledge in the field of renoprotective actions of sitagliptin, namely, improvement in diabetic dysmetabolism, hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective properties.
糖尿病肾病（DN）是目前全球范围内导致终末期肾病（ESRD）的单一最常见原因，也是糖尿病患者死亡的主要原因之一。它也被认为是心血管疾病（CVD）的独立危险因素。西他列汀获得批准以来，许多研究表明，它不仅能改善代谢控制，而且由于潜在的细胞保护特性，还能改善各种糖尿病靶向器官的功能障碍，特别是肾脏，其抗凋亡、抗氧化、抗炎和抗纤维化特性。尽管有总体建议，但许多患者的血糖控制仍长期严重超标，因此发生微血管和大血管并发症的风险增加。目前，越来越清楚的是，2 型糖尿病（T2DM）的管理不仅必须改善血糖控制，而且还必须预防胰腺恶化和并发症的进展，如 DN。这篇综述旨在概述西他列汀在肾脏保护作用方面的最新知识，即改善糖尿病代谢紊乱、血液动力学因素、肾功能、糖尿病肾脏病变和细胞保护特性。
